Quest Diagnostics Director Robert B. Carter Purchases 3,864 Shares via Dividend Reinvestment Plan on July 22, 2026

Director Robert B. Carter's Share Purchase Through Dividend Reinvestment Plan

Robert B. Carter, serving on the board of Quest Diagnostics, completed the acquisition of 3,864 common shares on July 22, 2026, at $206.804 per share, amounting to roughly $800,000 in value. The shares were obtained through a dividend reinvestment plan (DRIP), which automatically converts dividend payments into additional company stock at the market price on the transaction date.

DRIPs are widely used by publicly traded companies to allow shareholders to reinvest dividends into more shares automatically. Carter's broker administered the plan, and the acquired shares qualified for deferred reporting under SEC Rule 16a-6. However, Carter chose to file the transaction early on Form 4 instead of waiting for the standard Form 5 deadline, demonstrating a commitment to transparency for investors and regulators.

Transaction Specifics and Regulatory Filing Details

The transaction took place on July 22, 2026, with the disclosure filed five days later on July 27, 2026. The filing was submitted by Sean D. Mersten, acting as attorney-in-fact for Carter, following insider trading disclosure protocols. Carter's principal address is listed as 500 Plaza Drive, Secaucus, New Jersey, and he is identified solely as a Quest Diagnostics director without additional officer roles.

The filing indicates this was a straightforward acquisition of non-derivative securities, meaning Carter purchased actual common stock rather than options or warrants. The shares are held directly, granting Carter beneficial ownership and voting rights. No derivative transactions or adjustments were reported in connection with this purchase.

Beneficial Ownership Status Post-Acquisition

After this transaction, Carter's total beneficial ownership in Quest Diagnostics common stock stands at 3,864 shares. The filing does not specify his prior holdings, so investors interested in historical ownership changes should consult earlier Form 4 filings or company proxy statements.

These shares are directly owned by Carter, including full voting rights and entitlement to dividends. There are no reported indirect ownership arrangements such as trusts or family entities associated with these shares. This direct ownership is typical for board members maintaining personal stakes in their companies.

Insider Trading Compliance and Early Disclosure

The filing notes that shares were acquired under a dividend reinvestment plan, which normally allows for deferred reporting on Form 5 under Rule 16a-6. This rule permits automatic dividend reinvestment transactions to be reported less frequently, typically within 45 days after fiscal year-end. Carter's decision to file Form 4 within two business days reflects a voluntary early disclosure, enhancing transparency.

This proactive reporting approach signals Carter’s commitment to insider trading transparency. Although the SEC provides safe harbor provisions to ease administrative burdens, many insiders opt for immediate Form 4 filings to provide timely information to the market. This may also reflect internal compliance policies requiring prompt disclosure of all insider transactions.

Role of Robert B. Carter on Quest Diagnostics Board

Robert B. Carter serves as a director of Quest Diagnostics, a leading provider of diagnostic services including clinical laboratory testing, drug screening, and health and wellness solutions across the U.S. Directors at publicly traded companies like Quest Diagnostics oversee corporate strategy, financial performance, risk management, and executive compensation. Carter’s ongoing share acquisitions via dividend reinvestment may indicate confidence in the company’s growth and financial health.

Board members at major healthcare companies carry significant responsibilities including attending meetings, serving on committees, and collaborating with management. Maintaining personal investments in the company is common practice and sometimes mandated by governance policies. Carter’s additional share purchases through DRIP demonstrate his continued financial commitment beyond his board duties.

Market Price Context of the Share Acquisition

The shares were purchased at $206.804 each, reflecting the market price on July 22, 2026, when dividends were converted into shares. This price corresponds to the closing or trading price on that date, as the DRIP uses the prevailing market price for share purchases.

The filing does not comment on Carter’s view of the price relative to the company’s intrinsic value or future outlook. Since dividend reinvestment plans operate automatically, purchases occur regardless of price attractiveness. For some investors, insider participation in DRIPs is viewed as a neutral indicator of confidence given the systematic nature of the investment.

Regulatory Framework and Insider Transaction Disclosure

Under Section 16 of the Securities Exchange Act of 1934, directors, officers, and beneficial owners of more than 10% of a company’s securities must file Form 4 within two business days of transactions. These filings provide the SEC, company management, and investors with timely insight into insider trading activity, helping to reduce information asymmetry and prevent insider trading abuses.

As a NASDAQ-listed company, Quest Diagnostics complies with these reporting requirements. The company’s transfer agent and compliance programs monitor dividend reinvestment activities to ensure timely Form 4 filings. Carter’s filing, submitted via his attorney-in-fact, adheres to standard disclosure protocols, detailing the security, transaction date, price, and resulting ownership.

Dividend Reinvestment Plan Operation and Investor Benefits

Dividend reinvestment plans convert cash dividends into additional shares at the market price on the reinvestment date, allowing shareholders to grow their holdings without receiving cash payouts. This approach benefits long-term investors, including insiders, by compounding returns without requiring active dividend reinvestment decisions.

Carter’s DRIP was broker-administered, meaning his brokerage firm handled the conversion of dividends into shares. Many brokers offer DRIPs as a no-fee service, providing a transparent and systematic way for investors and insiders to reinvest dividends while maintaining regulatory compliance documentation.

Insider Transaction Transparency and Monitoring

This disclosure adds to the publicly available record of insider transactions at Quest Diagnostics accessible via the SEC’s EDGAR database and financial data platforms. Investors tracking insider buying and selling can analyze such data to gauge insider sentiment. Repeated insider purchases, whether through DRIPs or open market buys, may be interpreted as a positive sign of confidence in the company’s future.

The filing remains permanently accessible and searchable by company, insider, and date. Analysts, investors, and governance advocates routinely monitor these filings to identify trends in insider trading. While a single DRIP transaction may have limited significance alone, consistent accumulation by insiders over time can provide meaningful insights into management’s evaluation of shareholder value and company prospects.